Ranbaxy Exits Pfizer's Suit Over Generic Rapamune

Law360, New York (February 6, 2012, 7:32 PM EST) -- Ranbaxy Laboratories Ltd. on Monday exited a patent infringement suit launched by Pfizer Inc. against it and Watson Pharmaceuticals Inc. in Delaware federal court in response to abbreviated new drug applications to introduce a generic version of the organ rejection drug Rapamune.

In a sealed order, U.S. District Judge Richard G. Andrews signed off on a joint stipulation of dismissal without prejudice, allowing the company and its subsidiaries Ranbaxy Pharmaceuticals Inc. and Ranbaxy Inc. to exit the suit with each side bearing its own attorneys' fees...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.